Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.04 USD | -2.76% |
|
-1.06% | -40.80% |
06-10 | Sector Update: Health Care Stocks Retreat Monday Afternoon | MT |
06-10 | JPMorgan Initiates $525 Million Loan for ModivCare Refinancing | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The stock, which is currently worth 2024 to 0.51 times its sales, is clearly overvalued in comparison with peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Sales forecast by analysts have been recently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.80% | 370M | C- | ||
+25.01% | 88.62B | C+ | ||
-22.75% | 76.58B | B- | ||
+3.24% | 26.87B | C+ | ||
-8.76% | 17.48B | B | ||
+1.00% | 17.11B | A- | ||
+0.23% | 15.35B | A- | ||
+78.95% | 13.21B | C+ | ||
+71.14% | 13.16B | C- | ||
-24.74% | 12.98B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MODV Stock
- Ratings ModivCare Inc.